Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain

[1] Salar A(1997)Distribution and incidence rates of lymphoid neoplasms according to the REAL classification in a single institution. A prospective study of 940 cases Eur J Haematol. 59 231-237

[2] Fernández de Sevilla A(1998)Epidemiology of the non-Hodgkin’s lymphomas: distribution of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project Ann Oncol. 9 717-720

[3] Romagosa V(2014)Non-Hodgkin’s Lymphomas, Version 2.2014 J Natl Compr Canc Netw. 12 916-946

[4] Domingo-Claros A(2011)Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol. 22 vi59-vi63

[5] Gonzalez-Barca E(2011)Spanish Hematology and Hemotherapy Association; Oncological Group for the Treatment of Lymphatic Diseases; Spanish Lymphomas/Autologous Bone Marrow Transplant Group. Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma Leuk Lymphoma. 52 1-14

[6] De Sanjosé S(2014)Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study Ann Hematol. 93 1717-1724

[7] Pera J(2014)The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States Cancer. 120 1830-1837

[8] Servitje O(2013)R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi J Clin Oncol. 31 1506-1513

[9] Grañena A(2013)Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial Lancet. 381 1203-1210

[10] Anderson JR(2014)First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial Lancet Haematology 1 e104-e111

[1] Salar A(1997)Distribution and incidence rates of lymphoid neoplasms according to the REAL classification in a single institution. A prospective study of 940 cases Eur J Haematol. 59 231-237

[2] Fernández de Sevilla A(1998)Epidemiology of the non-Hodgkin’s lymphomas: distribution of the major subtypes differ by geographic locations. Non-Hodgkin’s Lymphoma Classification Project Ann Oncol. 9 717-720

[3] Romagosa V(2014)Non-Hodgkin’s Lymphomas, Version 2.2014 J Natl Compr Canc Netw. 12 916-946

[4] Domingo-Claros A(2011)Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol. 22 vi59-vi63

[5] Gonzalez-Barca E(2011)Spanish Hematology and Hemotherapy Association; Oncological Group for the Treatment of Lymphatic Diseases; Spanish Lymphomas/Autologous Bone Marrow Transplant Group. Clinical practice guidelines for first-line/after-relapse treatment of patients with follicular lymphoma Leuk Lymphoma. 52 1-14

[6] De Sanjosé S(2014)Maintenance with rituximab is safe and not associated with severe or uncommon infections in patients with follicular lymphoma: results from the phase IIIb MAXIMA study Ann Hematol. 93 1717-1724

[7] Pera J(2014)The use and effectiveness of rituximab maintenance in patients with follicular lymphoma diagnosed between 2004 and 2007 in the United States Cancer. 120 1830-1837

[8] Servitje O(2013)R-CVP versus R-CHOP versus R-FM for the initial treatment of patients with advanced-stage follicular lymphoma: results of the FOLL05 trial conducted by the Fondazione Italiana Linfomi J Clin Oncol. 31 1506-1513

[9] Grañena A(2013)Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial Lancet. 381 1203-1210

[10] Anderson JR(2014)First-line response-adapted treatment with the combination of bendamustine and rituximab in patients with mucosa-associated lymphoid tissue lymphoma (MALT2008-01): a multicentre, single-arm, phase 2 trial Lancet Haematology 1 e104-e111